Intestinal transport of glucose and amino acids in experimental uremia

Intestinal transport of organic food compounds and drugs: A scoping review on the alterations observed in chronic kidney disease

BACKGROUND AND AIMS

Around 850 million people worldwide are affected by chronic kidney disease (CKD). Patients with CKD often develop malnutrition and sarcopenia and changes in the pharmacokinetics of drugs. A reduced kidney function partially explains the prolonged half-life of certain drugs due to decreased renal clearance, which leads to an increased risk of adverse effects. While the intestine plays a fundamental role in this context, a systematic review of the effects of CKD on intestinal transport is lacking. We aimed to systematically summarize all the available evidence on intestinal transport of organic food components (carbohydrates/sugar, proteins/amino acids, fats, vitamins) and drugs (including drug transporters) in CKD.

METHODS

We conducted a systematic search of all the articles published until the 1st of April 2024, on five databases i.e. Embase, PubMed, Web of Science Core Collection, Cochrane Library, and Scopus. This systematic review was registered on the Open Science Framework (OSF) (osf.io/5e6wb) and was carried out according to the PRISMA 2020 guidelines.

RESULTS

From 9205 articles identified, 68 met the inclusion criteria. Absorption of organic food compounds seems to be altered, in general, and reduced for vitamins. The expression of intestinal efflux drug transporters may be altered in CKD.

CONCLUSIONS

Despite alterations in intestinal transport is suggested to be altered in CKD, the lack of recent studies, the paucity of human data and the heterogeneity of the methodologies used underscore the need for more research on the effect of CKD and uremia on intestinal transport.

Effect of 1,25-dihydroxyvitamin D3 on intestinal glucose absorption in uremic rats

The effect of 1,25-dihydroxyvitamin D3 (1,25-D) on the absorption of glucose in the small intestine was studied in five-sixths nephrectomized uremic rats and sham-operated rats. Four weeks after the nephrectomy, the uremic animals were divided into two groups: One group was given 1,25-D (300 pmol/kg body weight/day, three times per week) intraperitoneally, and the other was left untreated. One week after the 1,25-D treatment, an in vivo glucose absorption test was performed at 00.00 h in consideration of the circadian rhythm of glucose absorption. In untreated uremic rats, the glucose absorption rate was lower than in sham-operated rats. In 1,25-D treated uremic rats, the glucose absorption rate was higher than in untreated uremic rats and not lower than in sham-operated rats. These results suggest that the absorption rate of glucose of the small intestine is reduced in uremic rats and that it is recovered on treatment with 1,25-D.